Omslagafbeelding van de show OncoTalks | Oncology Insights at Your Fingertips

OncoTalks | Oncology Insights at Your Fingertips

Podcast door Ontada Learn

Engels

Technologie en Wetenschap

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode.Elk moment opzegbaar.

  • 20 uur luisterboeken / maand
  • Podcasts die je alleen op Podimo hoort
  • Gratis podcasts
Probeer gratis

Over OncoTalks | Oncology Insights at Your Fingertips

OncoTalks is the podcast for community oncology providers and clinicians who want to stay on top of new treatments and the latest advancements in oncology. Join Ontada Learn and community oncologists from The US Oncology Network as they explore oncology with a focus on the latest breakthroughs in cancer care. Expect concise, impactful discussions with practical clinical insights tailored for the real-world community oncology setting. Additionally, don’t miss OncoTalks Case Journeys, where experts deep dive into oncology patient cases and treatment journeys. Join as they conduct comprehensive case reviews, explore key learnings, and discuss the latest research and advances related to each case. Tune into OncoTalks and start unlocking pathways to better patient care today!

Alle afleveringen

17 afleveringen

aflevering Provider Perspectives on BTKi Selection in CLL artwork

Provider Perspectives on BTKi Selection in CLL

In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access, and long-term adherence. Learn how thoughtful treatment selection and patient-centered education can help improve outcomes throughout the CLL treatment journey. Listen to Navigating the CLL Treatment Landscape: The Role of Physician Choice [https://oncotalks.podbean.com/e/navigating-the-cll-treatment-landscape-the-role-of-physician-choice/] as Dr. Levy discusses why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Gisteren - 12 min
aflevering Navigating the CLL Treatment Landscape: The Role of Physician Choice artwork

Navigating the CLL Treatment Landscape: The Role of Physician Choice

In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personalized therapy selection is more critical than ever, yet step therapy requirements and payer restrictions are increasingly shaping clinical decisions. Dr. Levy shares real-world insights on how these policies affect patient outcomes, treatment adherence, and provider workload. Tune in to explore why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

13 jul 2026 - 7 min
aflevering Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer artwork

Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

20 mrt 2026 - 12 min
aflevering From Guidelines to Practice: Navigating Biomarker Testing in NSCLC artwork

From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.   Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

6 feb 2026 - 7 min
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Makkelijk in gebruik!
App ziet er mooi uit, navigatie is even wennen maar overzichtelijk.

Kies je abonnement

Meest populair

Premium

20 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 14 dagen gratis
Daarna € 9,99 / maand

Probeer gratis

Premium Plus

100 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 30 dagen gratis
Daarna € 13,99 / maand

Probeer gratis

Alleen bij Podimo

Populaire luisterboeken

Veelgestelde vragen

Meer vragen & antwoorden
Probeer gratis

Probeer 14 dagen gratis. € 9,99 / maand na proefperiode. Elk moment opzegbaar.